乳がん Breast Cancer の続きメーカー番号品名種類トナー数スホット数概要付属情報 Relapsed ER+ breast cancers with treatment Herceptin (Trastuzumab) eligible breast

Size: px

Start display at page:

Download "乳がん Breast Cancer の続きメーカー番号品名種類トナー数スホット数概要付属情報 Relapsed ER+ breast cancers with treatment Herceptin (Trastuzumab) eligible breast"

つねときさかいざわ
5 years ago
Views:

1 Top Enabling Tissue-Based Biomarker Research ヒト組織アレイ一覧 v.1403 がん検体は全て手術またはバイオプシー由来です採取から固定までの時間は 2~10 分ですアレイ上の殆どのドナーは FFPE ブロックからの大きい切片および凍結サンプルが提供可能ですアレイ内容は予告なしに変更する場合があります各アレイの詳細情報はお問い合わせください早見リンク乳がんがん幹細胞大腸がん血液がん肺がん卵巣がん膵臓がん前立腺がん頭頸部癌食道がん腎がん胃癌膀胱がん脳腫瘍マルチ腫瘍炎症性腸疾患関節リウマチ正常組織乳がん Breast Cancer Breast Cancer Tissue Array 100 FFPE primary tumors, 10 matched nodal metastases, 10 normal breast samples. Single 1mm Approx 55 samples Stages I & II,, ER, PR, HER2 (IHC) approx 25 samples Stage III Breast cancer 100 with molecular data FFPE primary tumors, 10 matched nodal metastases, 10 normal breast samples. Single 1mm Approx 55 samples Stages I & II,, ER, PR, HER2 (IHC), HER2 (FISH), Ki67 approx 25 samples Stage III Breast paired nodal metastases FFPE primary tumors, 30 paired nodal metastases. Single 1mm, ER, PR, HER2 (IHC), Ki Breast cancers primary & paired distant metastases FFPE primary tumors, with 15 matched paired distant metastasis samples. 1mm, ER, PR, HER2 (IHC), Ki Breast cancer heterogeneity array FFPE donors, 3 each from 3-4 different primary tumor blocks per donor and paired nodal metastases. 1mm, ER, PR, HER2 (IHC), Ki Triple negative breast cancer (HH) Triple negative breast cancer B Triple negative breast cancer with follow up Relapsed ER+ breast cancers FFPE triple negative breast cancer donors. 1-2 /donor, 5 normal breast 1mm FFPE Triple negative breast cancers. Single 1mm FFPE Triple negative breast cancers. Duplicate 1mm <Same donors as in > FFPE ER+ breast cancers, Stages II and III. Single 1mm Diagnosis, ER, PR, HER2 ER, PR, HER2, Ki67 ER, PR, HER2, Ki67, metastases ost surgery (months), site of metastasis, (months) treatment & response (RECIST) Stage, ER, PR, HER2, Ki67 次のページに続く 1 / 8 ページ

2 乳がん Breast Cancer の続きメーカー番号品名種類トナー数スホット数概要付属情報 Relapsed ER+ breast cancers with treatment Herceptin (Trastuzumab) eligible breast cancer TMA with treatment Breast cancer prognosis array 450 with treatment Breast cancer prognosis array 2000 FFPE ER+ breast cancers Stage II & III (same donors as ). Single 1mm FFPE Trastuzumab eligible breast cancers. 10 Stage II, 30 Stage III. Adjuvant setting, Trastuzumab responders and non-responders. Duplicate 1mm FFPE breast cancers with follow-up. Includes ER+/ER-, HER2+/HER2-, triple negative. FFPE breast cancers with follow-up. Single 0.6mm Stage, ER, PR, HER2, Ki67, treatment, site of progression, response (RECIST) ER, PR, HER2, Ki67, metastases post surgery (months), site of metastasis, treatment & response (RECIST) ER, PR, HER2, Ki67, metastases post surgery (months), site of metastasis, (months) treatment & response (RECIST) Age, Diagnosis, Grade, pt, pn, all nodes, positive nodes, BRE grade, (raw & tumor specific), hormonal therapy (Y/N), cytotoxic therapy (Y/N), pre-operative chemotherapy (Y/N) がん幹細胞 Cancer Stem Cells Human Cancer Stem Cell (CSC) cytoinclusion array with matched CSC generated xenografts FFPE CSCs isolated from human primary tumors. Matched xenografts from selected CSCs. Cancer types: Breast, colon, lung, glioblastoma and melanoma. Age, gender 大腸がん Colon Cancer メーカー番号品名種類トナー数スホット数概要付属情報 Colorectal Cancer Tissue Array Colon cancer 100 with molecular data Colon cancer progression array Colon cancer heterogeneity array FFPE primary tumors (Mainly advanced stage tumors III & IV) and 5 normal colon samples. FFPE primary tumors (Mainly advanced stage tumors III & IV), 5 normal colon samples. FFPE adenoma and 10 normal colon tissues. 50 low grade adenoma, 50 high grade adenoma, 50 pt2, 50 pt3, 50 nodal metastases and 50 liver metastases. FFPE donors, 3 each from 3-4 different primary tumor blocks per donor and paired nodal metastases. 1mm status, BRAF, p53 (tumor & adjacent), beta catenin (normal adjacent) status, 次のページに続く 2 / 8 ページ

3 大腸がん Colon Cancer の続き Colon adenoma array FFPE Approx. 25 high grade & 75 low grade Age, gender & grade adenomas Colon cancer liver metastases array FFPE Primary CRC (Stage IV) with matched liver metastases & 5 unmatched liver metastases. 1mm Colon cancer paired nodal metastases Colon cancer Stage II-III with KRAS data Colon cancer Stage IV with KRAS data Colon cancer with Cetuximab treatment Colon cancer with bevacizumab treatment II Colon cancer prognosis array 300 with treatment Colon cancer prognosis array 600 FFPE primary tumors, 30 paired nodal metastases. 1mm FFPE CRC with KRAS mutation data (WT and mutations G12V, G13D, G12D, G12C, G12A). Triplicate 1mm FFPE CRC with KRAS mutation data (WT and mutations G12V, G13D, G12D, G12C, G12A). Triplicate 1mm FFPE CRC with follow up including cetuximab treatment & response. Stage IV CRC, metastatic. KRAS WT, EGFR IHC data. Duplicate 1mm FFPE CRC with KRAS mutation status, follow up including bevacizumab treatment (metastatic & adjuvant) & response. Stage II, III CRC (adjuvant setting) & Stage IV (metastatic setting). Duplicate 1mm FFPE colon cancers. 80 donors Stage I/II, 200 donors Stage III/IV, 15 matched & unmatched liver metastases, 8 normal colons. Single 1mm FFPE colon cancers. 175 donors Stage I/II, 400 donors Stage III/IV, 15 matched & unmatched liver metastases, 10 normal colon. Single 1mm status, EGFR (IHC), site of met & months post surgery, treatment & response (RECIST) status, site of met & months post surgery, treatment & response (RECIST), site of met, treatment & response (RECIST), site of met, treatment & response (RECIST) 血液がん Hematological Cancers Multiple Myeloma 15 FFPE plasmacytoma samples from bone marrow. Stages (Salmon and Durie): 1, 2, 3A. Single Age, gender, diagnosis, stage, organ 0.6mm Non-Hodgkin s Lymphoma FFPE diffuse large B cell lymphoma, 20 follicular Age, gender, diagnosis, location lymphoma, 10 CLL/SLL. Single 1mm Non-Hodgkin s Lymphoma with diagnostic and follow up FFPE diffuse large B cell lymphoma, 20 follicular lymphoma, 10 CLL/SLL with follow up & diagnostic IHC markers. Single 1mm <Same donors as > Age, gender, diagnosis, location. IHC diagnostic markers, treatment, response & Diffuse large B cell lymphoma (DLBCL) FFPE diffuse large B cell lymphoma. Single 1mm Age, gender, diagnosis, location 次のページに続く 3 / 8 ページ

4 血液がん Hematological Cancers の続きメーカー番号品名種類トナー数スホット数概要付属情報 Diffuse large B cell lymphoma (DLBCL) with diagnostic and follow up FFPE diffuse large B cell lymphoma with follow up & diagnostic IHC markers. Single 1mm <Same donors as > Age, gender, diagnosis, location. IHC diagnostic markers, treatment, response & Recurrent Diffuse large B FFPE diffuse large B cell lymphoma (recurrent) Age, gender, diagnosis, cell lymphoma (DLBCL) with follow up & diagnostic IHC location. IHC diagnostic markers. markers, treatment, response & Myelodisplastic syndrome FFPE Myelodisplastic syndrome (MDS), single Age, gender, diagnosis (MDS) 1mm AML FFPE AML, duplicate 0.6mm Diagnosis 肺がん Lung Cancer Lung Cancer Tissue Array (NSCLC) 130 FFPE lung cancers (NSCLC). Stages I-III, Adenocarcinoma (60 samples), squamous cell carcinoma (50) lother sub-types (20). Single 1mm KRAS mutation, EGFR mutation, c-met (IHC) Lung Cancer Tissue Array FFPE lung cancers (NSCLC). Stages I-III, (NSCLC) 250 Adenocarcinoma (100 samples), squamous cell carcinoma (120), other sub-types (30). Single 1mm KRAS mutation, EGFR mutation, c-met (IHC) Lung Cancer Tissue Array (NSCLC) 350 FFPE lung cancers (NSCLC). Stages I-III, Adenocarcinoma (140 samples), squamous cell carcinoma (160), other sub-types (50). KRAS mutation, EGFR mutation, c-met (IHC) Lung cancer heterogeneity array FFPE donors, 3 each from 3-4 different primary tumor blocks per donor. 1mm KRAS mutation, EGFR mutation, c-met (IHC) Lung cancer EGFR diagnostics TMA FFPE Lung cancers with EGFR (IHC, exon sequencing, FISH) and KRAS (sequencing) data. Duplicate 0.6mm pt, pn, UICC stage, EGFR (IHC), EGFR mutation (sequencing), KRAS mutation (sequencing), Gene EGFR (avg.), centromere (avg), result, EGFR=/> Small cell lung cancer (SCLC) FFPE SCLC donor samples (including 6 with follow up data) plus 10 normal lung Duplicate 0.6mm Age, gender, diagnosis. Follow up data on selected samples includes smoking status, site of met, treatment and Lung cancer prognosis array 400 with treatment FFPE NSCLC donor samples. Stages I-III, Adenocarcinoma (140 samples), squamous cell carcinoma (160) and other sub-types (50). Single 1.0mm treatment &. KRAS mutation, EGFR mutation, c-met (IHC). Survival data for all samples, treatment for 80 samples 次のページに続く 4 / 8 ページ

5 肺がん Lung Cancer の続き Lung cancer prognosis array 400 with treatment FFPE NSCLC donor samples. Stages I-III, Adenocarcinoma (140 samples), squamous cell carcinoma (160) and other sub-types (50). Single 1.0mm treatment &. KRAS mutation, EGFR mutation, c-met (IHC). Survival data for all samples, treatment for 80 samples Lung cancer prognosis array 480 FFPE NSCLC donor samples. 90 ADC, 280 SCC, 40 bronchioloalveolar, 70 large cell, 4 neuroendocrine. Single 0.6mm *Release in 1Q 2014 TNM, (tumor specific & raw ), radiotherapy (Yes/No), Chemotherapy (Yes/No). 卵巣がん Ovarian Cancer Ovarian Cancer 100 FFPE ovarian cancers. 76 serous papillary carcinoma, 9 Adenocarcinoma NOS, 2 Clear Age, diagnosis, grade, TNM, stage cell adenocarcinoma, 4 Endometrioid Adenocarcinoma, 9 Mucinous Adenocarcinoma. Stages III/IV. Duplicate 1.0mm Ovarian cancer prognosis array 100 with treatment FFPE ovarian cancers. Duplicate 1mm <Same donors as > Age, diagnosis, grade, TNM, stage, setting (adjuvant/metastatic), treatment, follow up (RECIST),, KRAS mutation, AKTI mutation 膵臓がん Pancreatic Cancer Pancreatic cancer primary & matched metastases FFPE pancreatic adenocarcinoma with paired nodal metastases and 2 normal samples. Age, diagnosis, grade, TNM, stage Pancreatic Cancer prognosis array FFPE pancreatic adenocarcinomas. Single 1mm Age, diagnosis, grade, TNM, stage, (raw & tumor specific) 5 / 8 ページ

6 前立腺 Prostate Cancer Prostate Cancer Array 150 FFPE prostate adenocarcinomas. 1mm from one or more blocks per donor Prostate cancer array (includes hormone FFPE prostate cancers, adenocarcinoma including hormone refractory. Gleason sum refractory) 6-9. Duplicate 1mm Prostate cancer heterogeneity array FFPE donors, 3 each from 3-4 different primary tumor blocks per donor. 1mm *Release in 1Q Prostate cancer progression array 100 FFPE BPH, PIN, pt2b, pt3b, hormone refractory, Gleason 8-9, normal control tissues. Single 1mm Hormone refractory prostate cancers FFPE hormone refractory prostate cancers. Biochemical criteria: Testosterone level lower than 0.5, and increases in PSA higher than 2 in two serial determinations separated by one week. Clinical criteria: radiological or bone scan progression Duplicate 1mm Prostate cancer prognosis array 500 FFPE prostate cancers with 5 year follow up. Single 0.6mm Age, diagnosis, pt, pn, Gleason scoring, PSA level, censor recurrence 頭頸部癌 Head and Neck Cancer Head & neck cancer 80 FFPE head & neck cancers. Tongue (15), oral Age, gender, location, TNM cavity (15), pharynx (28), lip (25). Single 1mm Head & neck cancer 80 with follow up data FFPE head & neck cancers. Tongue (15), oral cavity (15), pharynx (28), lip (25). Single 1mm <Same donors as > Age, gender, location, TNM, smoking status, treatment, PFS, overall Head & neck cancer 80 with follow up data & HPV status FFPE head & neck cancers. Single 1mm Age, gender, location, TNM, smoking status, treatment, PFS, overall. HPV status Head & neck cancer 95 FFPE head & neck cancers. Larynx (70), tongue (14) other sites (9). Single 1mm Age, gender, location, grade,, smoking status Head & neck cancer 95 with follow up data FFPE head & neck cancers. Larynx (70), tongue (14) other sites (9). <Same donors as in > Age, gender, location, diagnosis, grade, TNM, treatment, response (RECIST), Head & neck cancer 95 with follow up data & HPV status FFPE head & neck cancers. Larynx (70), tongue (14) other sites (9). <Same donors as in >. Age, gender, location, diagnosis, grade, TNM, treatment, response (RECIST),, HPV status 6 / 8 ページ

7 食道がん Esophageal Cancer Esophageal cancer 100 FFPE primary tumors, 20 matched nodal metastases, 20 normal tissues. 25 adenocarcinoma, 35 small cell carcinoma. 腎がん Renal Cancer Renal Cell Carcinoma 60 FFPE primary renal cell carcinomas. Mix of grades & stages. 胃癌 Gastric Cancer Gastric Cancer 90 FFPE gastric cancers. Mix of diffuse & intestinal types, adenocarcinoma, antrum, body GE junction. Single 1mm TNM Gastric cancer 90 with FFPE gastric cancers. Mix of diffuse & intestinal follow up data types, adenocarcinoma, antrum, body GE junction. <Same donors as > TNM, treatment, response, 膀胱がん Bladder Cancer Bladder Cancer 90 FFPE bladder cancers, 7 matched metastases, 3 unmatched metastases, 10 normal bladder TNM samples. T1-4a, N0-3, M0-1. Single 1mm Bladder Cancer 90 with follow up data FFPE bladder cancers, 7 matched metastases, 3 unmatched metastases, 10 normal bladder with follow up data (treatment, response, ). <Same donors as > TNM, treatment, response, 脳腫瘍 Brain Tumor Glioblastoma Multiforme 100 FFPE Grade IV GBM including recurrences and radiotherapy data, 5 normal. Duplicate 0.6mm Age, gender, radiotherapy (yes/no) Medulloblastoma 50 FFPE medullloblatsoma, 10 PNETs. Medulloblastoma WHO grade IV, spnet WHO grade IV. Duplicate 0.6mm Age, gender, diagnosis 7 / 8 ページ

8 マルチ腫瘍 Multi-Tumor Multi Tumor 120 FFPE tumor types, 12 donor samples each. Tumor types: Breast, Age, Gender, Diagnosis, Tumor Grade & Stage Colorectal, Prostate, Lung, Ovarian, Head & Neck, Melanoma, Bladder, Renal Cell and Pancreatic Multi Tumor 450 FFPE tumor types, donor samples each. Duplicate 1mm Tumor types: Breast, Colon, Lung (NSCLC), Lung (SCLC), Prostate, Ovarian, Gastric, Head & Neck, Kidney, Melanoma, Bladder, Endometrial, Lymphoma, Thryroid. Age, Gender, Diagnosis, Tumor Grade & Stage 炎症性腸疾患 Inflammatory Bowel Disease Inflammatory Bowel Disease (Crohn's disease & ulcerative colitis) FFPE Crohn's disease & 10 ulcerative colitis, single 1mm Age, gender, diagnosis 関節リウマチ Rheumatoid Arthritis Rheumatoid Arthritis FFPE rheumatoid arthritis samples. Single 1mm Age, gender, diagnosis 正常組織 Normal Tissues Normal Tissue 96 FFPE normal human tissues, 3 donors each. Age, gender Tissue types: Stomach (fundus), stomach (muscle), heart, skin, uterus (myometrium), exocervix, lymph node, spleen, thymus, Ileum, colon descendens, gallbladder, liver, ureter, parotid gland, kidney (cortex), kidney (medulla), prostate, testis, ovary, lung, (parenchyma), breast (glands), endocervix, endometrium, placenta (early), seminal vesicle, adrenal gland, thyroid, cerebellum (cortex), cerebrum, urinary bladder (urothelium), fallopian tube Normal breast FFPE Single 1mm Age Normal colon FFPE Single 1mm Age, gender Normal prostate FFPE Single 1mm Age Normal lung/bronchus FFPE Single 1mm Age, gender Normal bladder/urothelium FFPE Single 1mm Age, gender 8 / 8 ページ

Table 1. Numbers of Cancerous Pleurisy Cases According to Primary Site Table 2. Histological Type of Lung Carcinoma with Cancerous Pleurisy at Autopsy

Clinicopathological Studies on Cancerous Pleurisy, with Emphasis on Extra-Pulmonary Malignancy Table 1. Numbers of Cancerous Pleurisy Cases According to Primary Site Table 2. Histological Type of Lung

乳がん Breast Cancer の続き メーカー番号品名種類ト ナー数スホ ット数概要付属情報 Relapsed ER+ breast cancers with treatment Herceptin (Trastuzumab) eligible breast

乳がん Breast Cancer の続きメーカー番号品名種類トナー数スホット数概要付属情報 Relapsed ER+ breast cancers with treatment Herceptin (Trastuzumab) eligible breast